[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-370362-105":59,"doc-detail-370362-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","stellar-304-a-phase-iii-study-of-zanzalintinib-xl092-plus-nivolumab-in-advanced-non-clear-cell-renal-cell-carcinoma","STELLAR-304 - a phase III study of zanzalintinib (XL092) plus nivolumab in advanced non-clear cell renal cell carcinoma","","Advanced non-clear cell renal cell carcinoma (nccRCC) is difficult to manage because of its rarity and biological heterogeneity. Combining a multi-targeted tyrosine kinase inhibitor (TKI) with an immune checkpoint inhibitor (ICI) is a promising strategy, but phase III randomized trials are required to establish superiority. Zanzalintinib is a novel multi-targeted TKI with encouraging preclinical activity when paired with ICIs. STELLAR-304 is a phase III first-line trial comparing zanzalintinib plus nivolumab versus sunitinib in advanced nccRCC, assessing progression-free survival and objective response rate, with overall survival as a secondary endpoint, and is registered as NCT05678673.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/stellar-304-a-phase-iii-study-of-zanzalintinib-xl092-plus-nivolumab-in-advanced-non-clear-cell-renal-cell-carcinoma/370362/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/stellar-304-a-phase-iii-study-of-zanzalintinib-xl092-plus-nivolumab-in-advanced-non-clear-cell-renal-cell-carcinoma/370362.png","ImageObject",300,407,{"name":92,"@type":93},"Riley","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-21","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",18,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What problem does STELLAR-304 address in advanced non-clear cell renal cell carcinoma?","Question",{"text":113,"@type":114},"STELLAR-304 targets the unmet need in advanced nccRCC, where outcomes are challenging due to the disease’s rarity and heterogeneity and limited dedicated randomized evidence for this setting.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How does STELLAR-304 compare treatments, and what is the study design?",{"text":118,"@type":114},"The phase III study evaluates first-line zanzalintinib plus nivolumab versus sunitinib, using random assignment in a 2-to-1 ratio to assess disease control and patient outcomes.",{"name":120,"@type":111,"acceptedAnswer":121},"What endpoints does STELLAR-304 use to evaluate effectiveness?",{"text":122,"@type":114},"Primary endpoints are progression-free survival and objective response rate, while overall survival is a secondary endpoint.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},370362,1790288423,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":39,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":46,"preview_page_count":19,"preview_urls":145},1374391975076,"https://ap-avatar.wpscdn.com/avatar/14000253ca4ec9f6853?x-image-process=image/resize,m_fixed,w_180,h_180&k=1783305029341752051","FUTURE ONCOLOGY  \n2025, VOL. 21, NO. 7, 787–794  \n[https://doi.org/10.1080/14796694.2025.2458395](https://doi.org/10.1080/14796694.2025.2458395)  \nCLINICAL TRIAL PROTOCOL  \nSTELLAR-304: a phase III study of zanzalintinib (XL092) plus nivolumab in advanced non-clear cell renal cell carcinoma  \nSumanta K. Pal a, Thomas Powlesb, Ravindran Kanesvaran c, Javier Molina-Cerrillo d, Darren R. Feldman e, Pedro Barata f, Mohan Liu g, Aarohi Bhatth, Zhong Wangi, Prachi Nandoskarh and Cristina Suarez j  \naDepartment of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA; bDepartment of Genitourinary Oncology, Barts Health NHS Trust Saint Bartholomew’s Hospital, London, UK; cDivision of Medical Oncology, National Cancer Centre Singapore, Singapore; dMedical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain; eDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; fDepartment of Medicine, University Hospitals Seidman Cancer Center, Cleveland, OH, USA; gClinical Collaborations, Bristol Myers Squibb, New York, NY, USA; hClinical Development, Exelixis, Inc., Alameda, CA, USA; iBiometrics, Exelixis, Inc., Alameda, CA, USA; jVall d´Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d’Hebrón, Vall d´Hebron Barcelona Hospital Campus, Barcelona, Spain  \nABSTRACT  \nManagement of advanced non-clear cell renal cell carcinoma (nccRCC) is challenging due to disease rarity and heterogeneity. The combination of multi-targeted tyrosine kinase inhibitor (TKI) with immune checkpoint inhibitor (ICI) has emerged as an effective treatment strategy, but well-designed, phase III randomized clinical trials are needed to demonstrate superiority over current treatment options. Zanzalintinib is a novel, multi-targeted TKI that has demonstrated promising preclinical anti-tumor activity in combination with ICIs. STELLAR-304 is a phase III trial evaluating first-line zanzalintinib plus nivolumab versus sunitinib in advanced nccRCC. Primary endpoints are progression-free survival and objective response rate. Secondary endpoint is overall survival. To our knowledge, STELLAR-304 is the first phase III study assessing a TKI-ICI combination in nccRCC patients across multiple subtypes. Clinical Trial Registration: This trial is registered at [ClinicalTrials.gov](ClinicalTrials.gov) (identifier: NCT05678673)  \nPLAIN LANGUAGE SUMMARY  \nAdvanced non-clear cell renal cell carcinoma (nccRCC) is a group of rare kidney cancers that have spread to other parts of the body. Currently available treatment options for nccRCC are based on results from phase II studies for nccRCC involving small numbers of patients or from studies conducted for all kidney cancers; these treatments may not adequately control the disease. Therefore, new and effective therapies are urgently needed. Zanzalintinib is an investigational oral drug that may reduce or stop cancer cells from growing and spreading. Zanzalintinib may also improve how well the body responds to another type of cancer drug called immune checkpoint inhibitor (ICI), which works by helping the body’s own immune system attack cancer cells. STELLAR-304 is a global, phase III study in people who have not been previously treated for advanced nccRCC. The study will test how zanzalintinib plus nivolumab, an ICI, can control the disease compared with sunitinib, a therapy commonly used to treat nccRCC. Participants will be randomly assigned in a 2 to 1 ratio to receive either zanzalintinib plus nivolumab or sunitinib. We will compare how long participants stay alive without nccRCC worsening and evaluate how their tumor responds to the two study treatments. Additionally, we will monitor the side effects in the treatment groups. Approximately 291 participants will be included.  \nARTICLE HISTORY  \nReceived 21 June 2024 Accepted 22 January 2025  \nKEYWORDS  \nZanzalintinib; XL092; nivolumab; sunitinib; non-clear cell renal cell carcinoma; t","cbCaiqfdgPNCNQax","https://ap.wps.com/l/cbCaiqfdgPNCNQax","pdf",4275574,"English","# Background\n## Unmet need and current treatment landscape in non-clear cell renal cell carcinoma","[{\"question\":\"What problem does STELLAR-304 address in advanced non-clear cell renal cell carcinoma?\",\"answer\":\"STELLAR-304 targets the unmet need in advanced nccRCC, where outcomes are challenging due to the disease’s rarity and heterogeneity and limited dedicated randomized evidence for this setting.\"},{\"question\":\"How does STELLAR-304 compare treatments, and what is the study design?\",\"answer\":\"The phase III study evaluates first-line zanzalintinib plus nivolumab versus sunitinib, using random assignment in a 2-to-1 ratio to assess disease control and patient outcomes.\"},{\"question\":\"What endpoints does STELLAR-304 use to evaluate effectiveness?\",\"answer\":\"Primary endpoints are progression-free survival and objective response rate, while overall survival is a secondary endpoint.\"}]","STELLAR-304 - a phase III study of zanzalintinib (XL092) plus nivolumab in advanced non-clear cell renal cell carcinoma | PDF",1790188174,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/35a36b455e4f502169f9236ad7924958.webp",983,1280,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/515ce48ec4f0529f6a8184905c63e05c.webp",982,1278,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/21a2073a831cf907937437ff78f260b7.webp",981,1277,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b2692caca0f81c40aabfa5a685fa552c.webp",980,1276]